These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 12568403

  • 1. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.
    Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U, Boyce BF.
    J Bone Miner Res; 2003 Feb; 18(2):260-9. PubMed ID: 12568403
    [Abstract] [Full Text] [Related]

  • 2. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF.
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [Abstract] [Full Text] [Related]

  • 3. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
    Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J.
    J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
    [Abstract] [Full Text] [Related]

  • 4. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [Abstract] [Full Text] [Related]

  • 5. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K.
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [Abstract] [Full Text] [Related]

  • 6. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA.
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [Abstract] [Full Text] [Related]

  • 7. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T.
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [Abstract] [Full Text] [Related]

  • 8. IL-1 plays an important role in the bone metabolism under physiological conditions.
    Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y.
    Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
    [Abstract] [Full Text] [Related]

  • 9. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X, Huang Y, Collin-Osdoby P, Osdoby P.
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [Abstract] [Full Text] [Related]

  • 10. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT.
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [Abstract] [Full Text] [Related]

  • 11. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E.
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [Abstract] [Full Text] [Related]

  • 12. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.
    Life Sci; 2007 Mar 13; 80(14):1311-8. PubMed ID: 17306833
    [Abstract] [Full Text] [Related]

  • 13. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
    O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC.
    Am J Physiol Endocrinol Metab; 2005 Nov 13; 289(5):E784-93. PubMed ID: 15956054
    [Abstract] [Full Text] [Related]

  • 14. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD, Horwood NJ, Chuman Y, Fisher JL, Ellis J, Martin TJ, Rubin JS, Gillespie MT.
    J Bone Miner Res; 2004 Nov 13; 19(11):1873-81. PubMed ID: 15476588
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K, Kudo A.
    J Bone Miner Res; 2005 May 13; 20(5):840-7. PubMed ID: 15824857
    [Abstract] [Full Text] [Related]

  • 17. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 13; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 13; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.